Over the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Click here to see the full list of 39 stocks from our Undervalued US Small Caps With Insider Buying screener.

Let's uncover some gems from our specialized screener.

ACNB

Simply Wall St Value Rating: ★★★☆☆☆

Overview: ACNB is a financial services company primarily engaged in banking and insurance operations, with a market capitalization of $0.29 billion.

Operations: The company's primary revenue streams are from its banking and insurance segments, with banking contributing significantly more. Operating expenses are a major cost component, consistently exceeding $60 million in recent periods. The net income margin has shown variability, reaching as high as 34.31% in June 2023 before declining to 27.58% by September 2024.

PE: 13.7x

ACNB Corporation, a smaller company by market capitalization, has recently shown insider confidence with share purchases. Despite a decrease in net income to US$7.2 million for Q3 2024 from US$9.04 million the previous year, the company maintains its appeal through strategic buybacks and dividend growth, increasing its quarterly dividend by 6.7% to US$0.32 per share. Looking ahead, earnings are projected to grow at an annual rate of 18.75%, suggesting potential for future value appreciation despite current challenges.

• Get an in-depth perspective on ACNB's performance by reading our valuation report here.

• Learn about ACNB's historical performance.

Maravai LifeSciences Holdings

Simply Wall St Value Rating: ★★★★★☆

Overview: Maravai LifeSciences Holdings specializes in providing products and services for nucleic acid production and biologics safety testing, with a market capitalization of $1.88 billion.

Operations: Nucleic Acid Production is the primary revenue stream, generating $213.27 million, followed by Biologics Safety Testing at $63.65 million. The company has experienced fluctuations in its net income margin, with recent periods showing a decline to -81.13%. Gross profit margin also saw a decrease from 83.33% in early 2022 to 46.36% by late 2024.

PE: -2.9x

Maravai LifeSciences Holdings, a smaller player in the U.S. market, recently faced financial challenges with a net loss of US$99 million for Q3 2024, up from US$6.46 million last year, partly due to a goodwill impairment of US$154 million. Despite volatile share prices and reliance on external borrowing, insider confidence is evident as insiders purchased shares between August and October 2024. The company projects annual revenue between US$255 million and US$265 million for 2024.

• Unlock comprehensive insights into our analysis of Maravai LifeSciences Holdings stock in this valuation report.

• Review our historical performance report to gain insights into Maravai LifeSciences Holdings''s past performance.

Tilray Brands

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Tilray Brands operates in the cannabis, wellness, distribution, and beverage alcohol sectors with a focus on producing and distributing cannabis products globally; the company has a market capitalization of approximately $1.88 billion.

Operations: The company generates its revenue primarily from four segments, with cannabis and distribution being the largest contributors. Operating expenses are significant, impacting profitability, with general and administrative expenses consistently forming a large portion of these costs. The gross profit margin has shown variability over recent periods, reaching 30.31% in the latest data point provided.

PE: -5.6x

Tilray Brands, a player in the cannabis and beverage industry, recently showcased its innovative spirit with fall-themed product launches across its craft beer brands. Despite reporting a net loss of US$39.17 million for Q1 2024, an improvement from last year’s US$55.86 million loss, the company anticipates fiscal 2025 revenue between US$950 million to $1 billion. Insider confidence is evident as they have been purchasing shares since September 2024, suggesting belief in potential growth despite current unprofitability challenges.

• Navigate through the intricacies of Tilray Brands with our comprehensive valuation report here.

• Gain insights into Tilray Brands' past trends and performance with our Past report.

Key Takeaways

• Unlock more gems! Our Undervalued US Small Caps With Insider Buying screener has unearthed 36 more companies for you to explore.Click here to unveil our expertly curated list of 39 Undervalued US Small Caps With Insider Buying.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:ACNB NasdaqGS:MRVI and NasdaqGS:TLRY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com